These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27573624)

  • 21. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
    Ridley DB; Sánchez AC
    Lancet; 2010 Sep; 376(9744):922-7. PubMed ID: 20833303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of the Priority Review Voucher Program.
    Sarpatwari A; Kesselheim AS
    JAMA; 2016 Apr; 315(15):1660-1. PubMed ID: 27092839
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of the Priority Review Voucher Program.
    Ridley DB; Dent J; Egerton-Warburton C
    JAMA; 2016 Apr; 315(15):1659-60. PubMed ID: 27092837
    [No Abstract]   [Full Text] [Related]  

  • 24. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 25. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
    Bashaw ED
    Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development.
    Jain N; Hwang T; Franklin JM; Kesselheim AS
    JAMA; 2017 Jul; 318(4):388-389. PubMed ID: 28742898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 29. In defence of priority review vouchers.
    Sonderholm J
    Bioethics; 2009 Sep; 23(7):413-20. PubMed ID: 19659848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vouching for access.
    Nat Med; 2016 Jul; 22(7):693. PubMed ID: 27387878
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA program could boost treatments for neglected diseases.
    Traynor K
    Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
    Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
    Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 34. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ​US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access.
    Ridley DB; Ganapathy P; Kettler HE
    Health Aff (Millwood); 2021 Aug; 40(8):1243-1251. PubMed ID: 34339239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Drugs Approved in 2020.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2021 Sep; 134(9):1096-1100. PubMed ID: 33939997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerating drug development and approval.
    Cole P
    Drug News Perspect; 2010; 23(1):37-47. PubMed ID: 20155218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NIH program helps developers navigate path to new drugs for neglected diseases.
    Voelker R
    JAMA; 2012 Feb; 307(6):549-50. PubMed ID: 22318268
    [No Abstract]   [Full Text] [Related]  

  • 40. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.